Investigating Immune Mechanisms in Atopic Eczema
Primary Purpose
Atopic Dermatitis
Status
Withdrawn
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Skin biopsy
Skin suction blister
Mantoux test
Sponsored by
About this trial
This is an interventional basic science trial for Atopic Dermatitis
Eligibility Criteria
Inclusion Criteria:
- History of atopic dermatitis (according to United Kingdom Working Party's diagnostic criteria)
- Previous Bacillus Calmette-Guerin vaccination
Exclusion Criteria:
- Unable to give written informed consent
- Previous history of hypersensitivity to local anaesthetic (for skin biopsy) or tuberculin PPD (for skin test)
- Pregnancy or breast feeding
- History of tuberculosis
- Recent infection or immunisation (within last month)
- Known immunodeficiency e.g. HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
- Systemic steroids within the last month or any other immunosuppressive medications (eg. methotrexate, ciclosporin or azathioprine) within the previous 3 months
- Phototherapy within the previous 28 days
- Treatment with potent topical corticosteroids or tacrolimus ointment within the previous 7 days
- Significant co-morbidity (diabetes, renal failure, liver failure, heart failure)
- On warfarin or known bleeding disorder
- History of neoplasm in last 10 years (not including basal cell carcinoma)
- Previous keloid scarring
Sites / Locations
- Royal Free London NHS Foundation Trust
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
Skin biopsy
Skin suction blister
Mantoux, skin biopsy, suction blister
Arm Description
5mm skin punch biopsy on forearm
Skin suction blister induced on forearm
0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
Outcomes
Primary Outcome Measures
Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers
Secondary Outcome Measures
Full Information
NCT ID
NCT02102841
First Posted
March 31, 2014
Last Updated
April 27, 2021
Sponsor
University College, London
Collaborators
Dermatrust
1. Study Identification
Unique Protocol Identification Number
NCT02102841
Brief Title
Investigating Immune Mechanisms in Atopic Eczema
Official Title
Investigating the Role of Skin Resident T Cells in Atopic Eczema and Responses to Antigen Challenge
Study Type
Interventional
2. Study Status
Record Verification Date
April 2021
Overall Recruitment Status
Withdrawn
Why Stopped
Recruitment no longer feasible
Study Start Date
May 2014 (undefined)
Primary Completion Date
May 2017 (Anticipated)
Study Completion Date
May 2017 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
University College, London
Collaborators
Dermatrust
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
The aim of this study is to investigate the mechanisms behind the immune dysfunction that occurs in atopic eczema (or atopic dermatitis).
Detailed Description
Atopic eczema is a chronic inflammatory skin disease that affects 15-20% of children and 12% of adults and leads to significant loss of quality of life. It results from a complex interaction of genetic and environmental factors, and is characterised by dysregulation of the cutaneous immune system. Specifically, in the skin of eczema patients there is a persistence of T lymphocytes (a crucial cell involved in regulating the immune system), and an overproduction of certain cytokines (signalling molecules that are essential in producing inflammatory responses).
The study intends to investigate the causes of atopic eczema by examining the number, characteristics and function of T lymphocytes in the skin and the blood of eczema patients, as well as the types of cytokine they produce. To achieve this the investigators aim to take skin biopsies, tissue fluid (from induced skin suction blisters) and blood samples from adult eczema patients and healthy controls for analysis. Additionally, in these groups a cutaneous immune response will be initiated by injecting tuberculin protein purified derivative (the Mantoux test) into the skin, to further investigate how the behaviour of T lymphocytes varies between eczema patients and healthy controls.
This research is important in view of the high prevalence of atopic eczema in the population. An improved understanding of its causes will hopefully lead to more effective treatments for this condition in future.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atopic Dermatitis
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
0 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Skin biopsy
Arm Type
Experimental
Arm Description
5mm skin punch biopsy on forearm
Arm Title
Skin suction blister
Arm Type
Experimental
Arm Description
Skin suction blister induced on forearm
Arm Title
Mantoux, skin biopsy, suction blister
Arm Type
Experimental
Arm Description
0.1ml tuberculin purified protein derivative (PPD) is injected intradermally into an area of non-lesional skin on the volar aspect of each of the patient's forearms. This is followed by a skin biopsy on one arm and induction of a skin suction blister on the other arm.
Intervention Type
Procedure
Intervention Name(s)
Skin biopsy
Intervention Type
Procedure
Intervention Name(s)
Skin suction blister
Intervention Type
Biological
Intervention Name(s)
Mantoux test
Other Intervention Name(s)
Tuberculin PPD (SSI)
Primary Outcome Measure Information:
Title
Number of regulatory T cells in lesional skin of atopic dermatitis patients compared to healthy volunteers
Time Frame
Up to 14 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
History of atopic dermatitis (according to United Kingdom Working Party's diagnostic criteria)
Previous Bacillus Calmette-Guerin vaccination
Exclusion Criteria:
Unable to give written informed consent
Previous history of hypersensitivity to local anaesthetic (for skin biopsy) or tuberculin PPD (for skin test)
Pregnancy or breast feeding
History of tuberculosis
Recent infection or immunisation (within last month)
Known immunodeficiency e.g. HIV infection, primary immunodeficiency, any history of chemotherapy or radiotherapy
Systemic steroids within the last month or any other immunosuppressive medications (eg. methotrexate, ciclosporin or azathioprine) within the previous 3 months
Phototherapy within the previous 28 days
Treatment with potent topical corticosteroids or tacrolimus ointment within the previous 7 days
Significant co-morbidity (diabetes, renal failure, liver failure, heart failure)
On warfarin or known bleeding disorder
History of neoplasm in last 10 years (not including basal cell carcinoma)
Previous keloid scarring
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Malcolm Rustin, MBBS MRCP MD
Organizational Affiliation
Royal Free London NHS Foundation Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
Royal Free London NHS Foundation Trust
City
London
ZIP/Postal Code
NW3 2QG
Country
United Kingdom
12. IPD Sharing Statement
Citations:
PubMed Identifier
7918015
Citation
Williams HC, Burney PG, Hay RJ, Archer CB, Shipley MJ, Hunter JJ, Bingham EA, Finlay AY, Pembroke AC, Graham-Brown RA, et al. The U.K. Working Party's Diagnostic Criteria for Atopic Dermatitis. I. Derivation of a minimum set of discriminators for atopic dermatitis. Br J Dermatol. 1994 Sep;131(3):383-96. doi: 10.1111/j.1365-2133.1994.tb08530.x.
Results Reference
background
Learn more about this trial
Investigating Immune Mechanisms in Atopic Eczema
We'll reach out to this number within 24 hrs